Native IGF-1, produced mainly by the liver in response to growth hormone signaling, is one of the primary drivers of longitudinal bone growth and overall tissue development during childhood and adolescence. This is well-established endocrinology, not a contested finding, and it is why IGF-1 levels are used clinically as a diagnostic marker for growth hormone deficiency or excess in both children and adults.
This clinical role reflects decades of endocrinology research and is entirely separate from any discussion of engineered research analogs like IGF-1 LR3, which do not exist in the body and have no established clinical role.
Circulating IGF-1 levels rise through childhood, peak around puberty, and then decline gradually with age — a well-documented pattern in endocrinology literature. This age-related decline has made IGF-1 a subject of interest in aging research, though the research picture here is considerably more complex than the childhood-growth story.
Some research associates lower IGF-1 levels with age-related declines in muscle mass, bone density, and other markers of physical function, consistent with IGF-1's known growth-promoting role.
Other lines of research have found more complex, sometimes even inverse, associations between IGF-1 signaling and longevity in certain model organisms and experimental contexts — findings that have made IGF-1's overall relationship to aging and lifespan a genuinely active and unsettled area of study, rather than a simple "more is better" or "less is better" story.
This nuance is worth stating plainly: published research does not support a simple, one-directional claim about IGF-1 and aging in either direction, and general commentary that presents it that way is oversimplifying a genuinely complex literature.
It is worth being clear that this entire discussion concerns native, endogenous IGF-1 physiology — not IGF-1 LR3 or other engineered research analogs, which do not occur naturally in the body and have never been studied in the context of human aging or longevity. Conflating native IGF-1 biology with claims about laboratory research chemicals is a common source of misinformation in general peptide discussion.
IGF-1 LR3 remains, throughout, an unapproved laboratory research reagent — not a supplement, not a therapeutic, and not something REVIVE LAB UAE sells.
This article describes general, published endocrinology and aging-research findings. It is not medical advice about aging, hormone therapy, or any intervention, and readers with specific health questions should consult a licensed physician rather than general informational content.
REVIVE LAB UAE does not sell IGF-1 LR3 or provide guidance related to hormone therapy of any kind.